Supramolecular nanotherapeutics enable metabolic reprogramming of tumor‐associated macrophages to inhibit tumor growth
- 7 April 2022
- journal article
- research article
- Published by Wiley in Journal of Biomedical Materials Research Part A
- Vol. 110 (8) , 1448-1459
Abstract
Tumor‐associated macrophages (TAMs) exist in multiple phenotypes across the spectrum, defined by an M1 antitumorigenic phenotype and an M2 pro‐tumorigenic phenotype on two ends of the spectrum. A largely immunosuppressive tumor‐microenvironment aids the polarization of the infiltrating macrophages to a pro‐tumorigenic M2 phenotype that promotes tumor progression and metastasis. Recent developments in macrophage immunotherapy have focused on strategies to re‐educate TAMs from an M2 to M1 phenotype. Recent findings in the realm of immuno‐metabolism have indicated that distinct metabolic signatures accompany macrophages based on their polarization states (M1‐Glycolysis and M2‐TCA cycle). These metabolites are important drivers of cellular signaling responsible for acquiring these polarization states, with evidence showing that metabolism is essential to facilitate the energy requirements of immune cells and regulate immune cell response. We hypothesized that TAMs could be reprogrammed metabolically by co‐delivery of drugs using a supramolecular nanoparticle system that could effectively rewire macrophage metabolism by simultaneous inhibition of the TCA cycle and upregulation of the glycolytic metabolic pathway. TLR7/8 agonist and Fatty Acid Oxidation (FAO) inhibitor loaded metabolic supramolecular nanoparticles (MSNPs) were synthesized. In vitro assays showed macrophages treated with MSNPs were reprogrammed from an M2 phenotype to an M1 phenotype while significantly upregulating phagocytosis. When injected in 4T1 tumor‐bearing mice, MSNPs treatment reduced tumor growth progression more than other treatments. Hence, the delivery of TLR7/8 agonist combined with an FAO inhibitor can enhance antitumor efficacy through metabolic reprogramming of tumor‐associated macrophages.Keywords
Funding Information
- U.S. Department of War (W81XWH2010676D)
This publication has 26 references indexed in Scilit:
- The tumor microenvironment underlies acquired resistance to CSF-1R inhibition in gliomasScience, 2016
- Orally administered colony stimulating factor 1 receptor inhibitor PLX3397 in recurrent glioblastoma: an Ivy Foundation Early Phase Clinical Trials Consortium phase II studyNeuro-Oncology, 2015
- Structure-Guided Blockade of CSF1R Kinase in Tenosynovial Giant-Cell TumorNew England Journal of Medicine, 2015
- Myeloid Colony-Stimulating Factors as Regulators of Macrophage PolarizationFrontiers in Immunology, 2014
- Effect of miR-142-3p on the M2 Macrophage and Therapeutic Efficacy Against Murine GlioblastomaJNCI: Journal of the National Cancer Institute, 2014
- Tumor-Associated Macrophages Contribute to Tumor Progression in Ovarian CancerFrontiers in Oncology, 2014
- Tissue-resident macrophagesNature Immunology, 2013
- Pigmented villonodular synovitis therapy with MSCF-1 inhibitorsCurrent Opinion in Oncology, 2012
- Biocompatible phosphatidylcholine bilayer coated on magnetic nanoparticles and their application in the extraction of several polycyclic aromatic hydrocarbons from environmental water and milk samplesJournal of Chromatography A, 2012
- Are High Drug Loading Nanoparticles The Next Step Forward for Chemotherapy?Nanomedicine, 2012